Background Fully efficient vaccines against malaria pre-erythrocytic stage are still lacking.
The objective of this dose/adjuvant-finding study was to evaluate the safety, reactogenicity …

The SPf66 synthetic vaccine is safe and partly efficacious against Plasmodium falciparum
malaria among children 1–5 years old. The estimated vaccine efficacy [VE] for all clinical …

Background Stalled progress in controlling Plasmodium falciparum malaria highlights the
need for an effective and deployable vaccine. RTS, S/AS01, the most effective malaria …

The development of a malaria vaccine is a priority for improved and sustained malaria
control. Optimal use of a vaccine in Africa will only be achieved if it can be delivered through …

Background Ad35. CS. 01 is a pre-erythrocytic malaria candidate vaccine. It is a codon
optimized nucleotide sequence representing the P. falciparum circumsporozoite (CS) …

RTS, S/AS02A is a pre-erythrocytic malaria vaccine candidate in which a portion of the
circumsporozoite surface protein (CSP) of Plasmodium falciparum is genetically linked to …

We assessed a combination multi-stage malaria vaccine schedule in which RTS, S/AS01B
was given concomitantly with viral vectors expressing multiple-epitope thrombospondin …

Extensive control efforts have significantly reduced malaria cases and deaths over the past
two decades, but in recent years, coupled with the COVID-19 pandemic, success has …

Abstract Background The RTS, S/AS malaria candidate vaccine is being developed with the
intent to be delivered, if approved, through the Expanded Programme on Immunization (EPI) …

Significant progress has been made in the development of the malaria vaccine during the
last 20 years. Ninety percent of the 300–500 million clinical cases of malaria per year …